WO2022247063A1 - 苯磺酸左旋氨氯地平片及其制备方法 - Google Patents

苯磺酸左旋氨氯地平片及其制备方法 Download PDF

Info

Publication number
WO2022247063A1
WO2022247063A1 PCT/CN2021/118169 CN2021118169W WO2022247063A1 WO 2022247063 A1 WO2022247063 A1 WO 2022247063A1 CN 2021118169 W CN2021118169 W CN 2021118169W WO 2022247063 A1 WO2022247063 A1 WO 2022247063A1
Authority
WO
WIPO (PCT)
Prior art keywords
levamlodipine besylate
preparation
levamlodipine
tablet
besylate tablet
Prior art date
Application number
PCT/CN2021/118169
Other languages
English (en)
French (fr)
Inventor
王寿春
黄月娜
王小芳
Original Assignee
海南锦瑞制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 海南锦瑞制药有限公司 filed Critical 海南锦瑞制药有限公司
Publication of WO2022247063A1 publication Critical patent/WO2022247063A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the invention relates to the preparation of tablets, in particular to a levoamlodipine besylate tablet and a preparation method thereof.
  • Levoamlodipine besylate is a powerful dihydropyridine calcium channel blocker, which has the effect of dilating blood vessels and can be used to treat hypertension, angina pectoris and other diseases.
  • Amlodipine besylate has two isomers, left-handed and right-handed. The calcium ion activity of the left-handed isomer is 1000 times that of the right-handed isomer and twice that of the racemic form. Because the drug activity of the levo-isomer is significantly higher than that of the racemate, the resolution of amlodipine besylate is still a research focus in the preparation of levo-amlodipine besylate.
  • the methods for the preparation of enantiomerically pure amlodipine mainly focus on the resolution of the racemates, that is, the separation of amlodipine by stereoselective precipitation or the enantiomerization of the racemic mixture of amlodipine intermediates. body method.
  • the use of the diastereomeric salts of amlodipine is an effective method for the resolution of the isomers as they can be separated by physical means and can be easily neutralized with bases.
  • Most of the commercial methods for separating amlodipine isomers use D-(-)-tartaric acid or L-(+)-tartaric acid to form amlodipine diastereomeric salts, and then use appropriate solvents separate them.
  • U.S. Patent US6646131B2 and Chinese Patents CN00102701.8 and CN201410370738.7 disclose the use of tartaric acid as a resolution agent and deuterated dimethyl sulfoxide (DMSO-d 6 ) as a chiral auxiliary for resolution.
  • DMSO-d 6 deuterated dimethyl sulfoxide
  • This method can simultaneously Obtain two isomers of amlodipine, but DMSO-d 6 is very expensive, and the deuterated reagent has great toxicity, and its use is prohibited in the pharmaceutical industry, so it does not have industrial application prospects.
  • impurity D amlodipine 1,4-dihydropyridine ring reduction impurities
  • patents CN200580040627.9, CN200580040627.9 and CN201010128863.9 respectively use optically active O, O'-dibenzoyl-D-(-)-tartaric acid or O, O' -Dibenzoyl-L-(+)-tartaric acid is used as a resolving agent, and isopropanol is used as a resolving solvent for resolution;
  • patents WO2008/026838A1 and CN201010149029.8 use camphoric acid as a chiral resolving agent, and isopropanol
  • the above-mentioned method is resolved and the generation of still unavoidable impurity. Therefore, it is still a problem to be solved to find a preparation method of levoamlodipine besylate with mild reaction conditions, simple and convenient operation process, high product yield and purity, low production cost and suitable for industrial production.
  • magnesium stearate needs to be used as a glidant.
  • Magnesium stearate is a relatively common pharmaceutical excipient, which is usually used as a glidant, lubricant and anti-adhesive agent. A small amount of intake will not cause great harm to the human body, but long-term use will cause respiratory system, Diseases of the skin etc. Because of its hydrophobic nature, magnesium stearate has been reported to slow the rate at which medications and supplements dissolve in the gastrointestinal tract, directly affecting the body's ability to absorb chemicals and nutrients. Therefore, finding a safe and healthy glidant to replace magnesium stearate is also one of the research priorities in the preparation process of levamlodipine besylate tablets.
  • the invention provides a kind of levamlodipine besylate tablet and preparation method thereof.
  • a kind of levamlodipine besylate tablet, in parts by weight, the raw materials for making the active ingredients of said levamlodipine besylate tablet include: 3.47-7 parts of levamlodipine besylate, microcrystalline 40-120 parts of cellulose, 30-90 parts of sodium starch glycolate, 0.5-1 part of calcium phosphate and 5-10 parts of xylitol.
  • levamlodipine besylate is obtained by reacting levamlodipine with R-(-)-mandelic acid, and then directly reacting the obtained intermediate with benzenesulfonic acid.
  • the molar ratio of the racemic amlodipine to R-(-)-mandelic acid is 1.6-2:1; the molar ratio of the intermediate to benzenesulfonic acid is 1:1.1-1.2.
  • the solvent for the reaction between racemic amlodipine and R-(-)-mandelic acid is a mixed solution of N,N-dimethylformamide and water.
  • volume ratio of N,N-dimethylformamide to water is 3-8:1.
  • the solvent for the reaction between the intermediate and benzenesulfonic acid is a mixed solution of isopropanol and water.
  • volume ratio of the isopropanol to water is 1:3-7.
  • microcrystalline cellulose, sodium starch glycolate and calcium phosphate are obtained by drying at 60-80°C and passing through a 60-80 mesh sieve.
  • the xylitol is obtained by drying at 50-60°C and passing through a 60-80 mesh sieve.
  • a preparation method of levamlodipine besylate tablet is that after mixing all the raw materials, they are directly pressed into tablets to obtain the levamlodipine besylate tablet.
  • the combination of a certain proportion of calcium phosphate and xylitol can act as a glidant, and using it as a glidant, the prepared levamlodipine besylate tablets are complete, with good gloss and stable tablet weight , the angle of repose is less than 39°, and the hardness is greater than 55N; during the tableting process, it can be smoothly pressed, effectively suppressing the phenomenon of material blocking and punch sticking;
  • xylitol can also correct the taste of the drug, making it easy to take;
  • the present invention uses cheap R-(-)-mandelic acid as a resolution agent to resolve amlodipine to obtain S-(-)-amlodipine-R-(-)-mandelic acid salt with optical purity up to 99.83%, and not easily hydrolyzed, can directly react with benzenesulfonic acid to obtain levamlodipine besylate, with high yield and good purity (up to 99.96%), suitable for industrialized production;
  • using mandelic acid for resolution can also suppress the generation of impurity D.
  • Embodiment 1 A kind of preparation method of levamlodipine besylate
  • This embodiment is a preparation method of levamlodipine besylate, and the specific preparation process includes the following steps:
  • Embodiments 2 to 6 are respectively a preparation method of levamlodipine besylate, and their steps are basically the same as in Example 1, the difference is only in the amount of raw materials and process parameters, see Table 1 for details:
  • Example 2-6 The content of the other parts of Examples 2-6 is the same as that of Example 1.
  • the levamlodipine besylate prepared in Examples 1-6 has high yield and good purity.
  • Embodiment 7 A kind of preparation method of levamlodipine besylate tablet
  • Levoamlodipine besylate (from Example 1) 6.94g microcrystalline cellulose 100g Carboxymethyl Starch Sodium 85g calcium phosphate 0.8g Xylitol 8g production 1000 pieces
  • Embodiment 8 ⁇ 12 The preparation method of levamlodipine besylate tablet
  • Embodiments 8 to 12 respectively use the levamlodipine besylate prepared in Examples 2 to 6 to prepare levamlodipine besylate tablets, and their steps are basically the same as in Example 7, except that the amount of raw materials and the process are different. The parameters are different, see Table 3 for details:
  • Embodiments 8-12 The content of the other parts of Embodiments 8-12 is the same as that of Embodiment 1.
  • the levamlodipine besylate tablets prepared in Examples 7-12 are complete, have good gloss and stable tablet weight.
  • Comparative Examples 1 to 4 are comparative tests of the preparation process of Levoamlodipine Besylate Tablets [Specification: 5 mg in terms of Levoamlodipine] in Example 7, the difference is only in:
  • the amount of calcium phosphate in Comparative Example 1 was 1.5g, which could be pressed into tablets very well, with regular edges and no scattering, but the mouthfeel became worse, with lime flavor, tablet weight 0.15g ⁇ 2.6%, hardness 63N, angle of repose 37.12°;
  • the dosage of xylitol in Comparative Example 2 is 15g, which can be pressed well, with regular edges and no scattering, but it is too sweet and greasy, beyond the acceptable range.
  • the weight of the obtained tablet is 0.15g ⁇ 3.4%, the hardness is 59N, and the angle of repose is 38.07 °;
  • the consumption of calcium phosphate in the comparative example 3 is 0.1g, can't be well pressed tablet, tablet weight is unstable, edge is irregular, has scattered, gained tablet piece weight 0.15g ⁇ 12.4%, hardness 37N, angle of repose 44.7 °;
  • the feeding process cannot be continuous, the phenomenon of material blocking and punch sticking occurs, the vibration amplitude increases, the pressure curve is unstable, and the film cannot be continuously discharged;
  • the consumption of xylitol in the comparative example 4 is 1g, can't be well pressed tablet, and sheet weight is unstable, and edge is irregular, has scattered, and gained tablet sheet weight is 0.15g ⁇ 7.6%, hardness 43N, angle of repose 42.1 °;
  • the feeding process cannot be continuous, the phenomenon of material blocking and punch sticking occurs, the vibration amplitude increases, the pressure curve is unstable, and the film cannot be continuously discharged;
  • Comparative Example 5 prepares levamlodipine besylate tablets according to the method disclosed in the preparation embodiment 2 of the notification number CN103193700B, with regular edges and no scattering, the grammage of the tablet is 0.15g ⁇ 5.3%, the hardness is 58N, and the angle of repose is 39.12°.
  • Example 9 97.1 0.33 100.2
  • Example 11 97.3 0.24 100.06
  • Comparative example 2 95.2 0.31 100.10 Comparative example 5 95.8 0.46 99.94
  • the levamlodipine besylate tablet prepared by the present invention has a good dissolution rate, and its main drug content is high, and the content of related substances is low, so it is suitable for industrialized production.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明提供一种苯磺酸左旋氨氯地平片及其制备方法，属于药物制备技术领域，所述制备方法是取苯磺酸左旋氨氯地平3.47～7重量份、微晶纤维素40～120重量份、羧甲淀粉钠30～90重量份、磷酸钙0.5～1重量份及木糖醇5～10重量份混匀、压片，即得所述苯磺酸左旋氨氯地平片。本发明以合适比例的磷酸钙和木糖醇作为助流剂，制成的苯磺酸左旋氨氯地平片完整、光泽度好、片重稳定，休止角小于39°，硬度大于55N。

Description

苯磺酸左旋氨氯地平片及其制备方法 技术领域
本发明涉及片剂的制备，尤其涉及一种苯磺酸左旋氨氯地平片及其制备方法。
背景技术
苯磺酸左旋氨氯地平是一种功能强大的二氢吡啶钙通道阻滞剂，具有舒张血管的作用，可用于治疗高血压、心绞痛等疾病。苯磺酸氨氯地平有左旋和右旋两种异构体，左旋体的钙离子活性是右旋体的1000倍，是消旋体的2倍。由于左旋体的药物活性明显高于消旋体，因此对于苯磺酸氨氯地平的拆分仍是苯磺酸左旋氨氯地平制备过程中的一个研究重点。
目前，制备对映异构体纯氨氯地平的方法主要集中于拆分外消旋体，即通过立体选择性沉淀分离氨氯地平或合成氨氯地平中间体的外消旋体混合物对映异构体的方法。氨氯地平的非对映异构体盐的应用是拆分异构体的有效方法，因其可通过物理方法分离，并且可以利用碱轻易的中和。将氨氯地平异构体拆分的商用方法中大部分是应用D-(-)-酒石酸或L-(+)-酒石酸形成氨氯地平非对映异构体的盐，再应用适当的溶剂分离它们。1994年辉瑞公司发明了用酒石酸分离方式，拆分左旋氨氯地平，其产品光学纯度达99％，收率也很高，但该方法受限于利用二甲亚砜作为手性助剂，二甲亚砜的沸点(189℃)较高，在生产过程中易造成溶剂不易回收的问题，且由于二甲亚砜在加热回收过程中会产生剧烈的歧化反应，导致爆炸，工业生产危险性大；同时，二甲亚砜的凝点也较高，低于18℃就会凝固，也会给生产上带来很大的不便。
美国专利US6646131B2及中国专利CN00102701.8、CN201410370738.7中公开了利用酒石酸作为拆分剂，氘代二甲基亚砜(DMSO-d 6)做为手性助剂进行拆分，该方法可以同时得到氨氯地平的两个异构体，但DMSO-d 6价格非常昂贵，且氘代试剂具有很大的毒性，在制药工业上禁止使用，因此不具有工业应用前景。
随后，人们以酒石酸作为手性拆分剂，又进行了一系列研究，包括专利WO03035623A1、CN02825939.4、CN200910136780.1、CN201110418986.0、CN200310119335.7及CN200610076935.3等，但这些专利中，以酒石酸作为拆分剂对消旋体氨氯地平拆分时，除了各种溶剂对生产和环境造成的影响外，还存在母液难以降解处理等问题。此外研究发现，以酒石酸作为拆分剂进行拆分，易产生氨氯地平1,4-二氢吡啶环还原杂质(杂质D)，含量＞0.1％，且很难通过常规精制方法有效去除，以达到药用标准，该杂质化学结构如下所示：
Figure PCTCN2021118169-appb-000001
除采用酒石酸对氨氯地平拆分外，专利CN200580040627.9、CN200580040627.9和CN201010128863.9分别使用光学活性的O,O′-二苯甲酰基-D-(-)-酒石酸或O,O′-二苯甲酰基-L-(+)-酒石酸为拆分剂，异丙醇为拆分溶剂进行拆分；专利WO2008/026838A1和CN201010149029.8使用樟脑酸为手性拆分剂、异丙醇为拆分溶剂；上述方法进行拆分仍不可避免杂质的产 生。因此，寻找一条反应条件温和、操作过程简便、产品收率和纯度高、生产成本低、适合工业化生产的苯磺酸左旋氨氯地平的制备方法仍是目前需要解决的问题。
同时，现有的苯磺酸左旋氨氯地平片制备过程中，均需采用硬脂酸镁作为助流剂。硬脂酸镁作为较常见的药用辅料，其通常用作助流剂、润滑剂及抗粘剂，少量摄入并不会对人体带来很大的危害，但是长期使用会造成呼吸系统、皮肤等方面的疾病。由于硬脂酸镁具有疏水性，有报道表明硬脂酸镁可以减缓药物和补充剂在胃肠道中溶解的速度，直接影响身体吸收化学物质和营养物质的能力。因此，寻找安全健康的助流剂代替硬脂酸镁，也是苯磺酸左旋氨氯地平片制备过程中的研究重点之一。
发明内容
针对上述问题，本发明提供一种苯磺酸左旋氨氯地平片及其制备方法。
为实现上述目的，本发明所采用的技术方案为：
一种苯磺酸左旋氨氯地平片，以重量份数计，制成所述苯磺酸左旋氨氯地平片的有效成分的原料包括：苯磺酸左旋氨氯地平3.47～7份、微晶纤维素40～120份、羧甲淀粉钠30～90份、磷酸钙0.5～1份及木糖醇5～10份。
进一步的，所述苯磺酸左旋氨氯地平是取消旋氨氯地平与R-(-)-扁桃酸反应后，所得中间体再与苯磺酸直接反应制得。
进一步的，所述消旋氨氯地平与R-(-)-扁桃酸的摩尔比为1.6～2:1；所述中间体与苯磺酸的摩尔比为1:1.1～1.2。
进一步的，所述消旋氨氯地平与R-(-)-扁桃酸反应的溶剂为N,N-二甲基甲酰胺与水的混合溶液。
进一步的，所述N,N-二甲基甲酰胺与水的体积比为3～8:1。
进一步的，所述中间体与苯磺酸反应的溶剂为异丙醇与水的混合溶液。
进一步的，所述异丙醇与水的体积比为1:3～7。
进一步的，所述微晶纤维素、羧甲淀粉钠及磷酸钙分别是经60～80℃烘干后，过60～80目筛制得。
进一步的，所述木糖醇是经50～60℃烘干后，过60～80目筛制得。
一种苯磺酸左旋氨氯地平片的制备方法，是取所有原料混匀后，直接压片，即得所述苯磺酸左旋氨氯地平片。
本发明的苯磺酸左旋氨氯地平片及其制备方法的有益效果为：
通过研究发现，一定比例的磷酸钙和木糖醇配合能够起到助流剂的作用，利用其作为助流剂，制成的苯磺酸左旋氨氯地平片完整、光泽度好、片重稳定，休止角小于39°，硬度大于55N；在压片过程中，能够流畅压片，有效抑制堵料、粘冲头等现象；
同时，木糖醇还能够矫正药物口感，便于服用；
本发明以便宜的R-(-)-扁桃酸作为拆分剂，对氨氯地平进行拆分，得到S-(-)-氨氯地平-R-(-)-扁桃酸盐光学纯度可达99.83％，且不易水解，可直接与苯磺酸反应，得到苯磺酸左旋氨氯地平，收率高、纯度好(达99.96％)，适于工业化生产；
同时，使用扁桃酸进行拆分，还能够抑制杂质D的产生。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述。在下面的描述中阐述了很多具体细节以便于充分理解本发明，但是本发明还可以采用其 他不同于在此描述的其它方式来实施，本领域技术人员可以在不违背本发明内涵的情况下做类似推广，因此本发明不受下面公开的具体实施例的限制。
实施例1 一种苯磺酸左旋氨氯地平的制备方法
本实施例为一种苯磺酸左旋氨氯地平的制备方法，具体制备过程包括以下步骤：
1)S-(-)-氨氯地平-R-(-)-扁桃酸盐的制备
取950mL的N，N-二甲基甲酰胺和150mL的水(N，N-二甲基甲酰胺与水的体积比BL1＝6.33:1)，搅拌混合均匀，过滤后，得拆分助剂溶液备用；
取20.7g的R-(-)-扁桃酸加至200mL拆分助剂溶液中，搅拌溶解，过滤除去不溶物杂质，得拆分剂溶液备用；
取100g消旋氨氯地平加至700mL拆分助剂溶液中，搅拌溶解，过滤除去不溶物杂质，滤液中滴加拆分剂溶液，室温搅拌反应1h，加入微量的S-(-)-氨氯地平-R-(-)-扁桃酸盐晶种，继续室温搅拌析晶4h，减压过滤，用100mL冷丙酮洗涤，加压真空干燥10小时，得64.21g的S-(-)-氨氯地平-R-(-)-扁桃酸盐，收率46.80％，HPLC检测光学纯度为99.91％。
2)苯磺酸左旋氨氯地平的制备
取6g苯磺酸溶于20mL水(标记为第一次用水)，得苯磺酸水溶液；
取60mL异丙醇与240mL水(标记为第二次用水)混合，得异丙醇水溶液；
取50g的S-(-)-氨氯地平-R-(-)-扁桃酸盐直接溶解于300mL的异丙醇水溶液中，加入苯磺酸水溶液，此时体系中异丙醇与两次用水总和的体积比BL2＝1:4.33，室温搅拌析晶4h，过滤，滤饼用200mL冷水搅洗两次，40℃ 下鼓风烘干，即得50.37g白色或类白色的苯磺酸左旋氨氯地平固体，收率99.67％，HPLC检测光学纯度99.98％，未检出杂质D。
实施例2～6 苯磺酸左旋氨氯地平的制备方法
实施例2～6分别为一种苯磺酸左旋氨氯地平的制备方法，它们的步骤与实施例1基本相同，不同之处仅在于原料用量及工艺参数的不同，具体详见表1：
表1 实施例2～6中各项工艺参数一览表
Figure PCTCN2021118169-appb-000002
实施例2～6其它部分的内容，与实施例1相同。
实施例1～6制备的苯磺酸左旋氨氯地平收率高、纯度好。
实施例7 一种苯磺酸左旋氨氯地平片的制备方法
本实施例中苯磺酸左旋氨氯地平片的处方如下：
表2 处方(规格：以左旋氨氯地平计5mg)
苯磺酸左旋氨氯地平(来自实施例1) 6.94g
微晶纤维素 100g
羧甲淀粉钠 85g
磷酸钙 0.8g
木糖醇 8g
制成 1000片
本实施例中苯磺酸左旋氨氯地平片的制备方法，包括以下步骤：
S1)将微晶纤维素、羧甲淀粉钠、磷酸钙及木糖醇分别在60℃烘干2h，过60目筛，备用；
S2)分别取处方量的微晶纤维素、羧甲淀粉钠、磷酸钙及木糖醇，采用等量递加法，搅拌混匀，得混合辅料。
S3)混合辅料中加入处方量的苯磺酸左旋氨氯地平，搅拌充分混匀，取样检测合格(测定主药含量，计算片重)后，直接用8mm冲模压片，即得苯磺酸左旋氨氯地平片，边缘规则，无散落，所得片剂片重0.15g±1.4％，硬度为60N，休止角为37.85°。
实施例8～12 苯磺酸左旋氨氯地平片的制备方法
实施例8～12分别使用实施例2～6制备的苯磺酸左旋氨氯地平制备苯磺酸左旋氨氯地平片，它们的步骤与实施例7基本相同，不同之处仅在于原料用量及工艺参数的不同，具体详见表3：
表3 实施例8～12中各项工艺参数一览表
Figure PCTCN2021118169-appb-000003
实施例8～12其它部分的内容，与实施例1相同。
实施例7～12制备的苯磺酸左旋氨氯地平片完整、光泽度好、片重稳定。
实验例1 苯磺酸左旋氨氯地平片的性能测试
对比例1～4为实施例7中苯磺酸左旋氨氯地平片【规格：以左旋氨氯地平计5mg】的制备过程的对比试验，区别仅在于：
对比例1中磷酸钙的用量为1.5g，可以很好压片，边缘规则，无散落，但口感变差，有石灰味，片重0.15g±2.6％，硬度63N，休止角37.12°；
对比例2中木糖醇的用量为15g，可以很好压片，边缘规则，无散落，但过于甜腻，超出接受范围，所得片剂片重0.15g±3.4％，硬度59N，休止角38.07°；
对比例3中磷酸钙的用量为0.1g，无法很好压片，片重不稳定、边缘不规则、有散落，所得片剂片重0.15g±12.4％，硬度37N，休止角44.7°；进料过程无法连续，出现堵料、粘冲头现象，振动幅度增大，压力曲线不稳定，无法连续出片；
对比例4中木糖醇的用量为1g，无法很好压片，片重不稳定、边缘不规则、有散落，所得片剂片重0.15g±7.6％，硬度43N，休止角42.1°；进料过程无法连续，出现堵料、粘冲头现象，振动幅度增大，压力曲线不稳定，无法连续出片；
对比例5按照公告号CN103193700B的制剂实施例2中公开的方法制备苯磺酸左旋氨氯地平片，边缘规则，无散落，所得片剂克重0.15g±5.3％，硬度为58N，休止角为39.12°。
由于对比例3和4无法很好的制成苯磺酸左旋氨氯地平片，因此后续不再进行溶解度试验。
取实施例7～12和对比例1、2和5中制得的苯磺酸左旋氨氯地平片，按照《苯磺酸左旋氨氯地平片》【国家食品药品监督管理局国家药品标准WS 1-(X-020)-2002Z】中规定的方法测定溶出度、有关物质含量、左旋氨氯地平含量，具体检测结果见下表：
表4 检测结果一览表
实施例 溶出度(％) 有关物质含量(％) 左旋氨氯地平含量(％)
实施例7 98.2 0.21 100.05
实施例8 96.8 0.29 99.98
实施例9 97.1 0.33 100.2
实施例10 96.9 0.28 100.00
实施例11 97.3 0.24 100.06
实施例12 98.1 0.30 99.97
对比例1 93.4 0.32 99.94
对比例2 95.2 0.31 100.10
对比例5 95.8 0.46 99.94
由表4可以看出，本发明制备的苯磺酸左旋氨氯地平片具有很好溶出度，且其主药含量高，有关物质含量低，适合工业化生产。
显然，所描述的实施例仅仅是本发明的一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。

Claims (10)

  1. 一种苯磺酸左旋氨氯地平片，其特征在于，以重量份数计，制成所述苯磺酸左旋氨氯地平片的有效成分的原料包括：苯磺酸左旋氨氯地平3.47～7份、微晶纤维素40～120份、羧甲淀粉钠30～90份、磷酸钙0.5～1份及木糖醇5～10份。
  2. 根据权利要求1所述的苯磺酸左旋氨氯地平片，其特征在于，所述苯磺酸左旋氨氯地平是取消旋氨氯地平与R-(-)-扁桃酸反应后，所得中间体再与苯磺酸直接反应制得。
  3. 根据权利要求2所述的苯磺酸左旋氨氯地平片，其特征在于，所述消旋氨氯地平与R-(-)-扁桃酸的摩尔比为1.6～2:1；所述中间体与苯磺酸的摩尔比为1:1.1～1.2。
  4. 根据权利要求2或3所述的苯磺酸左旋氨氯地平片，其特征在于，所述消旋氨氯地平与R-(-)-扁桃酸反应的溶剂为N,N-二甲基甲酰胺与水的混合溶液。
  5. 根据权利要求4所述的苯磺酸左旋氨氯地平片，其特征在于，所述N,N-二甲基甲酰胺与水的体积比为3～8:1。
  6. 根据权利要求2、3或5所述的苯磺酸左旋氨氯地平片，其特征在于，所述中间体与苯磺酸反应的溶剂为异丙醇与水的混合溶液。
  7. 根据权利要求6所述的苯磺酸左旋氨氯地平片，其特征在于，所述异丙醇与水的体积比为1:3～7。
  8. 根据权利要求2、3、5或7所述的苯磺酸左旋氨氯地平片，其特征在于，所述微晶纤维素、羧甲淀粉钠及磷酸钙分别是经60～80℃烘干后，过60～80目筛制得。
  9. 根据权利要求2、3、5或7所述的苯磺酸左旋氨氯地平片，其特征在于，所述木糖醇是经50～60℃烘干后，过60～80目筛制得。
  10. 权利要求1-9中任一项所述的苯磺酸左旋氨氯地平片的制备方法，其特征在于，所述制备方法是取所有原料混匀后，直接压片，即得所述苯磺酸左旋氨氯地平片。
PCT/CN2021/118169 2021-05-28 2021-09-14 苯磺酸左旋氨氯地平片及其制备方法 WO2022247063A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110592106.5 2021-05-28
CN202110592106.5A CN113209035B (zh) 2021-05-28 2021-05-28 苯磺酸左旋氨氯地平片及其制备方法

Publications (1)

Publication Number Publication Date
WO2022247063A1 true WO2022247063A1 (zh) 2022-12-01

Family

ID=77099066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/118169 WO2022247063A1 (zh) 2021-05-28 2021-09-14 苯磺酸左旋氨氯地平片及其制备方法

Country Status (2)

Country Link
CN (1) CN113209035B (zh)
WO (1) WO2022247063A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113209035B (zh) * 2021-05-28 2022-07-08 海南锦瑞制药有限公司 苯磺酸左旋氨氯地平片及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193700A (zh) * 2011-08-19 2013-07-10 海南锦瑞制药股份有限公司 一种苯磺酸左旋氨氯地平晶体及含有该晶体的药物组合物
CN109069432A (zh) * 2016-03-17 2018-12-21 德国麦德斯医药有限公司 用于治疗高血压的包含氨氯地平、坎地沙坦西酯和氢氯噻嗪的固定剂量药物组合物
CN113209035A (zh) * 2021-05-28 2021-08-06 海南锦瑞制药有限公司 苯磺酸左旋氨氯地平片及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1262182A3 (en) * 1991-11-26 2003-02-26 Sepracor Inc. Methods and compositions for treating hypertension, angina and other disorders using optically pure(-) amlodipine
CN102125526A (zh) * 2010-01-12 2011-07-20 上海中邦斯瑞生物药业技术有限公司 氨氯地平分散片
CN104739799B (zh) * 2013-12-27 2018-01-05 辰欣药业股份有限公司 一种用于直接压片的苯磺酸氨氯地平组合物及其片剂制备方法
TW201717947A (zh) * 2015-08-20 2017-06-01 漢達生技醫藥股份有限公司 包含氨氯地平和右美沙芬的藥物組合物
WO2019135691A1 (en) * 2018-01-04 2019-07-11 Jamjoom Pharmaceuticals Factory Company Limited A stable mono-layer solid dosage form containing combination of two active ingredients
CN111377851B (zh) * 2018-12-30 2022-12-20 鲁南制药集团股份有限公司 一种苯磺酸左旋氨氯地平的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193700A (zh) * 2011-08-19 2013-07-10 海南锦瑞制药股份有限公司 一种苯磺酸左旋氨氯地平晶体及含有该晶体的药物组合物
CN109069432A (zh) * 2016-03-17 2018-12-21 德国麦德斯医药有限公司 用于治疗高血压的包含氨氯地平、坎地沙坦西酯和氢氯噻嗪的固定剂量药物组合物
CN113209035A (zh) * 2021-05-28 2021-08-06 海南锦瑞制药有限公司 苯磺酸左旋氨氯地平片及其制备方法

Also Published As

Publication number Publication date
CN113209035A (zh) 2021-08-06
CN113209035B (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
US20110046388A1 (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
US9408915B2 (en) Tolvaptan solid dispersion and its preparation method
WO2017020841A1 (zh) 一种含有lcz696的药物组合物及其制备方法
WO2016029828A1 (zh) AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
AU2013330603B2 (en) Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same
JP2017526699A (ja) （６ｓ）−５−メチルテトラヒドロ葉酸又はその塩の組成物及びその調製と応用
JP6159480B2 (ja) （−）−フペルジンａの調製
WO2022247063A1 (zh) 苯磺酸左旋氨氯地平片及其制备方法
JP6957807B2 (ja) 右旋性オキシラセタムの２型結晶、調製方法および用途
US11242340B2 (en) Crystal forms of demethyleneberberine hydrochloride and preparation method therefor
US10583087B2 (en) Pharmaceutical composition for oral administration
CN105001195B (zh) R(+)‑硫辛酸‑l‑赖氨酸盐的新晶型及其制备方法
EP3476835A1 (en) Crystal of quinoline derivative
CN107245054B (zh) 一种无定形草乌甲素化合物及其制备方法
CN102357093A (zh) 一种甲磺酸阿比朵尔口服固体制剂的药物组合物
CN103724266B (zh) 去甲伊伐布雷定盐及其制备方法和应用
CN110256300B (zh) 一种盐酸二甲双胍化合物及盐酸二甲双胍片组合物
CN106279017A (zh) 贝达喹啉晶型、组合物及其制备方法
CN105820157B (zh) 一种盐酸维拉佐酮晶型及其制备方法
CN104768927B (zh) (3s,3s’)‑4,4’‑二硫烷二基双(3‑氨基丁烷‑1‑磺酸)合l‑赖氨酸的新的结晶相
CN102552920B (zh) 一种含恩替卡韦的药物组合物及其制备方法
CN103508909A (zh) 一种琥珀酸美托洛尔晶型及其制备方法
WO2023160520A1 (zh) 一种三亚乙基四胺四氢氯化物及其制备方法与组合物
WO2014067281A1 (zh) 盐酸他喷他多晶型c及其制备方法和应用
CN102516338A (zh) 一种卡培他滨化合物、其药物组合物及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21942630

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21942630

Country of ref document: EP

Kind code of ref document: A1